Posizione ricoperta

Specialist in Ophthalmology

Esperienza professionale

Doctor in specialist training at U.O. Ophthalmology Clinic, Department of Neuroscience, University of Padua.

Istruzione e formazione

Specialization in Ophthalmology achieved on 05.19.15 at the University of Padua with a thesis entitled “Morphological and functional evaluation of the intravitreal dexamethasone implant in non-infectious intermediate and posterior uveitis complicated by macular edema” with a score of 110/110 and praise.
Doctor in specialist training at U.O. Ophthalmology Clinic, Department of Neuroscience, University of Padua.
Diabetic Retinopathy Screening Certification – NSC Based Training Course at Moorfields Eye Hospital London
Professional qualification obtained at the University of Padua in the second session of 2009 and registration in the Padua Medical Association on 03.23.2010 with no. 10547
Master’s degree in Medicine and Surgery obtained on 09.24.2009 at the University of Padua with a thesis entitled “Topical autologous serum and ocular surface in Graft versus Host Disease” with a score of 108/110

Pubblicazioni

Parrozzani R, Pilotto E, Dario A, Miglionico G, Midena E. Intravitreal triamcinolone versus intravitreal bevacizumab in the treatment of exudative retinal detachment secondary to posterior uveal melanoma. Am J Ophthalmol. 2013 Jan;155(1):127-133

Parrozzani R, Lazzarini D, Dario A, Midena E. In vivo confocal microscopy of ocular surface squamous neoplasia. Eye (London). 2011 Apr;25(4):455-60

Gruppi e Progetti

Projects

Sub investigator in the following clinical trials:
“A phase III, randomized, double-blinded study comparing the combination of the BRAFinhibitor, dabrafenib and the MEK inhibitor, trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (stage III/C) or metastatic (stage IV) BRAF V00E/K mutation-positive cutaneous melanoma”
“Evaluation of clinical outcomes after treatment with Systane® Balance in subjects suffering from dry eye with lipid layer deficiency”
“An 8-week phase I-II, multicenter, randomized, double-masked, vehicle controlled parallel group study with 48 or 56 week follow-up period to evaluate the safety and efficacy of two doses (10μg/ml and 20 μg/ml ) of recombinant human grouth factor eye drops solution versus vehicle in patient with stage 2 and 3 of Neurotrophic Keratitis.» 2013″
“A phase II/III, multicenter, double-masked, randomized, parallel group dose ringing, controlled trial of efficacy and tolerance of cyclosporine A (CsA) 0.05% and 0.1% ophthalmic cationic emulsion vrsus vehicle in patients vernal keratoconjunctivitis ”
“A randomized double masked and placebo controlled study to evaluate the efficacy and safety of sarilumab administered subcutaneously every 2 weeks in patients with non-infectious, intermediate, posterior or panuveitis”

Conferenze / Seminari

I nostri Specialisti in Ophthalmology